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Abstract: A single inhaler containing inhaled corticosteroid (ICS)/long-acting beta-agonist 
(LABA)/long-acting muscarinic antagonist (LAMA) is a more convenient way of delivering 
triple therapy in patients with COPD. Single triple therapy has been shown to be superior at 
reducing exacerbations and improving quality of life compared to LABA/LAMA, especially 
in patients with a prior history of frequent exacerbations and blood eosinophilia, who have 
ICS responsive disease. The corollary is that patients with infrequent exacerbations who are 
noneosinophilic may be safely de-escalated from triple therapy to LABA/LAMA without loss 
of control. Pointedly, there is a substantially increased risk of pneumonia associated with the 
triple therapy containing fluticasone furoate but not beclometasone dipropionate or budesonide. 
Since triple therapy is also better than ICS/LABA at reducing exacerbations and improving lung 
function, symptoms, and quality of life, this brings into question the rationale for using ICS/
LABA. Hence, we propose a simplified pragmatic decision process based on symptoms, prior 
to exacerbation history, and blood eosinophils to select which patients should be given a single 
triple inhaler or LABA/LAMA. Differences in patient preference of inhaler device, formulations 
and drugs will also determine which triple inhaler prescribers elect to use.
Keywords: COPD, inhaled corticosteroid, long-acting beta-agonist, long-acting muscarinic 
antagonist, lung function, exacerbation
Introduction
Single inhaler triple therapy containing inhaled corticosteroid (ICS) with long-acting 
beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) has been 
advocated for frequently exacerbating COPD patients, corresponding to group D of 
the GOLD guidelines.1 In light of recent clinical trials evaluating fluticasone furoate/
vilanterol/umeclidinium (FF/VIL/UMEC) and beclometasone dipropionate/formoterol/
glycopyrronium (BDP/FM/GLY),2,3 we thought it would be timely to briefly reappraise 
the current data of these two available closed single triple inhalers, especially in light 
of other pertinent data on open triple therapy (ie, two separate inhalers) for COPD.
The essential premise for using a triple inhaler in COPD, aside from improved adher-
ence, is that the ICS moiety will reduce exacerbations by suppressing the eosinophilic 
component of inflammation, while the LABA/LAMA will improve symptoms and exac-
erbations by improving airway caliber due to bronchodilator effects on airway smooth 
muscle (Figure 1). In addition, LAMA might also exhibit putative anti-inflammatory 
activity by antagonizing the paracrine mediated effects of acetylcholine on mucosal 
inflammatory cell chemotaxis and activation in addition to reducing mucus hyperse-
cretion.4 The potential downside of ICS is the potential for increased pneumonia risk, 
which raises the fundamental question regarding the overall relative benefit-risk equation 
(Figure 1). For example, in the TORCH trial comparing fluticasone propionate/salmeterol 
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(FP/SM) vs SM alone over 3 years, the number needed to treat 
was calculated as 44 to prevent one exacerbation and 16 to 
induce one pneumonia episode, giving a relative benefit-risk 
ratio for FP of 2.75.5 In this regard, there has been shown to be 
a marked difference in dose-related risk of serious pneumonia 
comparing FP and budesonide (BUD) in COPD.6
Considering the currently available triple inhalers, FF/VIL/ 
UMEC is a once daily dry powder inhaler (DPI) formulation 
(Trelegy Ellipta; GSK, Uxbridge, UK) while the BDP/FM/
GLY is a twice daily solution extra fine particle pressurized 
metered dose inhaler (pMDI) formulation (Trimbow; Chiesi, 
Parma, Italy). Patient preference and ability to use the dif-
ferent formulations will be important in determining which 
inhaler is best for an individual patient.
There is also a third triple cosuspension pMDI formula-
tion (PT010 Aerosphere; Luton, UK) in development cur-
rently in Phase III trials containing BUD with FM/GLY.
ICS withdrawal trials
In terms of determining the potential impact of the ICS 
moiety, it is pertinent to first consider the two pivotal trials 
which have looked at ICS withdrawal from prior open 
triple therapy.
The WISDOM randomized double blind trial enrolled 
2,485 patients who had experienced at least one exacerbation 
in the previous year.7 Seventy percent of patients were taking 
prior ICS at baseline and 49% were on open triple therapy. 
After an initial run-in on open triple therapy with FP/SM 
with tiotropium (TIO), patients were then randomized to con-
tinue on triple therapy (ICS continuation group) or SM/TIO 
(ICS withdrawal group) for 1 year. There was no difference 
in the primary end point of exacerbations but a significant 
43 mL mean fall in FEV
1
 after ICS withdrawal and no dif-
ference in pneumonia incidence. Post hoc analysis revealed a 
43% increase in exacerbations after ICS withdrawal in those 
Figure 1 Schematic to show effects of inhaled corticosteroid (ICS) moiety of single triple inhaler therapy in COPD.
Notes: (A, B) The benefit is shown as attenuation of bronchial mucosal eosinophilic inflammation resulting in reduced exacerbations; (B, C) risk depicted as impaired 
mucociliary function with mucus retention and altered microbiome following initial viral infection, along with prolonged bronchial/alveolar ICS retention and resulting local 
immunosuppression, in turn producing consolidation (pneumonia).
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patients who had blood eosinophils of at least 300 cells/µL in 
conjunction with two or more exacerbations in the past year, 
whereas there was no difference in patients with eosinophils 
less than 300/µL.8
The SUNSET randomized double blind trial in 1,033 
patients over 26 weeks looked at treatment de-escalation 
involving ICS withdrawal in infrequently exacerbating 
patients on prior triple therapy who, after initial run-in on 
FP/SM/TIO were then randomized to continue on open 
triple therapy or stepped down to once daily indacaterol/
glycopyrronium (IND/GLY) via DPI.9 There was a 26 mL 
difference in the primary end point of FEV
1
 and an 8% differ-
ence in exacerbations neither of which were significant. How-
ever, among 23% of patients who had blood eosinophils of at 
least 300/µL, there was a 69 mL lower mean FEV
1
 and 47% 
increase in exacerbations which were both significant.
real-life observational studies
Real-life observational data from a UK primary care database of 
GOLD A or B patients have also shown no differences in health 
resource use comparing open triple therapy vs LABA/LAMA.10 
The DACCORD real-life observational study from Germany 
looked at 377 infrequently exacerbating patients mostly GOLD 
B, who were switched to IND/GLY having previously been 
taking open triple therapy.11 Over the 1 year of follow-up after 
switching, there was no increase in exacerbations while 52% 
had a clinically relevant improvement in COPD Assessment 
Test score. Finally, in a Scottish observational study involving 
a time-dependent analysis of 2,853 patients followed-up for 
4.5 years, taking once daily TIO along with twice daily ICS/
LABA as separate inhalers was associated with 29% fewer 
exacerbations, 15% fewer hospital admissions, and 35% lower 
all-cause mortality compared to ICS/LABA alone.12
Taken together, these ICS withdrawal trials and observa-
tional studies indicate that among infrequently exacerbating 
GOLD B patients who were inappropriately receiving prior 
triple therapy, stepping down to LABA/LAMA appears to 
be a safe and cogent option, perhaps with the caveat that 
caution is required for the quarter of patients who have 
eosinophilic COPD.
Table 1 Key trials of single triple inhaler ICS/laBa/laMa vs dual inhalers as either ICS/laBa or laBa/laMa
Study Treatments Exacerbation 
rate/year
Difference/
year
% difference Time
to treat
(years)
IMPaCt* ICS/laBa/laMa
(n=4,151) vs
ICS/laBa
(n=4,134)
0.91 vs 1.07 0.16 15 6.25
IMPaCt* ICS/laBa/laMa (n=4,151) vs
laBa/laMa
(n=2,070)
0.91 vs 1.21 0.30 25 3.33
IMPaCt* ICS/laBa
(n=4,134) vs
laBa/laMa
(n=2,070)
1.07 vs 1.21 0.14 12 7.14
trIBUtE* ICS/laBa/laMa (n=764) vs
laMa/laBa
(n=768)
0.50 vs 0.59 0.09 15 11.11
trIlOGY ICS/laBa/laMa (n=687) vs
ICS/laBa
(n=680)
0.41 vs 0.53 0.12 23 8.33
FUlFIl ICS/laBa/laMa (n=911) vs
ICS/laBa
(n=899)
0.22 vs 0.34 0.12 35 8.33
KrONOS ICS/laBa/laMa (640) vs 
laBa/laMa (627)
0.46 vs 0.95 0.49 52 2.04
KrONOS ICS/laBa/laMa (640) vs 
ICS/laBa (316)
0.46 vs 0.56 0.10 18 10.0
KrONOS ICS/laBa (316) vs 
laBa/laMa (637)
0.56 vs 0.95 0.39 41 2.56
Notes: Data for each trial are shown as number of patients, moderate–severe exacerbation rate, absolute difference, percent relative reduction and time to treat 
(ie, number of years on treatment required to reduce one exacerbation in an average patient ). Key trials include: IMPaCt,2 trIBUtE,3 FUlFIl,13 trIlOGY,15 KrONOS.26 
asterisk denotes exacerbations were the primary end point.
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist.
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randomized controlled trials with single 
triple inhalers
There are four key randomized controlled trials that have 
compared single triple to dual combination inhalers (Table 1). 
The first key trial is the FULFIL study ranging over 24 weeks 
in 1,810 patients (53% GOLD B, 38% GOLD D) comparing 
FF/VIL/UMEC vs BUD/FM (turbuhaler), which for coprimary 
end points showed significant mean differences amounting 
to 171 mL in FEV
1
 and 2.2 units in St George’s Respiratory 
Questionnaire.13 Although there was a relative 35% reduction 
in annualized exacerbations conferred by the triple inhaler, 
absolute exacerbation rates were low. There was also a sig-
nificant difference in pneumonia rates which were 2.2% and 
0.8% for FF/VIL/UMEC vs BUD/FM respectively. However, 
this study may be criticized for comparing different ICS and 
LABA moieties via different DPI devices as well as once vs 
twice daily dosing regimes. As such these data are of limited 
value in terms of informing clinical decision-making.
The second trial is the IMPACT study which compared 
FF/VIL/UMEC to either VIL/UMEC or FF/VIL in 10,355 
patients over 1 year, all given once daily via the Ellipta device 
(GSK, Uxbridge, UK), powered on exacerbations.2 For the 
primary end point triple therapy reduced exacerbations by 
25% vs VIL/UMEC and 15% vs FF/VIL. The difference in 
exacerbations occurred within the first month of randomized 
treatment and thereafter the rates were parallel. The relative 
reduction in exacerbations comparing triple therapy to VIL/
UMEC was 32% for blood eosinophils of at least 150/µL 
and 12% for less than 150/µL, with only the former being 
significant. For lung function in comparison to triple therapy 
there was a 54 mL significant mean difference in FEV
1
 for vs 
VIL/UMEC and 97 mL vs FF/VIL, while for SGRQ the mean 
difference was -1.18 for both of the same comparisons. The 
transition dyspnea index (TDI) showed a significantly higher 
proportion of responders with triple vs either dual therapy. 
Pneumonia rates per 1,000 patient-years were 96 for triple 
therapy (8%), 97 for FF/VIL (7%), and 61 for VIL/UMEC 
(5%), amounting to respective increased risks of 57% and 
58% relative to VIL/UMEC. Compared to VIL/UMEC the 
on-treatment all-cause mortality rates were 42% and 39% 
lower with triple therapy and FF/VIL, respectively.
In summary, IMPACT2 showed that using two bronchodi-
lators in a single triple inhaler is better at reducing exacerba-
tions than using one as ICS/LABA, while the ICS moiety in 
the triple inhaler reduces exacerbations compared to LABA/
LAMA in the eosinophilic phenotype. However, the FF 
moiety in the triple inhaler or ICS/LABA had the downside 
of a substantially increased pneumonia risk. The relative 
benefit-risk ratio for FF/VIL vs VIL alone has previously 
been calculated for severe exacerbations and pneumonias 
requiring hospital admission in relation to blood eosinophils. 
For eosinophils .2%, there were 1.5 exacerbations prevented 
with FF in relation to inducing two pneumonias, while for 
.4%, there were five exacerbations and two episodes of 
pneumonias, per 100 patients over 1 year.14 The relative 
benefit-risk ratio for the triple inhaler in patients with counts 
of at least 300/µL remains to be established with regard to 
exacerbations and pneumonia.
In the TRILOGY study, a head-to-head comparison 
over 1 year was made of BDP/FM/GLY to BDP/FM both 
twice daily via pMDI in 1,368 patients who were mostly 
GOLD B.15 For the coprimary end points of trough and 
peak FEV
1
, the triple inhaler was superior by 81 mL and 
117 mL, respectively, compared to ICS/LABA, reflecting 
the additional bronchodilator effect of the LAMA. The 
third coprimary end point showed no significant differ-
ence in mean TDI score. In addition, for the secondary 
end point there was a 23% relative reduction in exacer-
bations with the triple inhaler, although absolute exacer-
bations rates were low in both treatment arms (Table 1).
The TRIBUTE study, over 1 year, compared BDP/FM/
GLY twice daily to IND/GLY once daily in 1,532 patients 
who were mostly GOLD B.3 The reason for choosing 
IND/GLY as the comparator arm was that it had been shown 
to be superior to FM/SM on exacerbations in the FLAME 
study.16 For the primary end point of exacerbations, there 
was a 15% overall relative reduction in favor of the triple 
inhaler but again absolute rates in both treatments were quite 
low (Table 1) and no overall difference was found in time 
to first exacerbation. In patients with eosinophils of at least 
2% the difference in exacerbations was 19% compared to 
6% in those with eosinophils less than 2%. Moreover, there 
were small but significant differences in trough FEV
1
 and 
SGRQ over the 52 weeks, while pneumonia occurred in 4% 
of patients in both groups.
Comparing TRIBUTE and IMPACT2,3, there are some 
important differences to point out. First, in IMPACT, 38% of 
patients were on prior triple therapy but none in TRIBUTE, 
whereas in both studies, over 60% of patients had been tak-
ing prior ICS. We wonder if perhaps acutely stopping ICS in 
patients subsequently receiving LABA/LAMA might in part 
explain the increased exacerbation risk which was evident in 
the first month of treatment in IMPACT. Such an effect of 
ICS cessation was not observed in WISDOM or SUNSET, 
although the latter enrolled patients with an infrequent 
exacerbation history. Another key difference is that 47% and 
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21% of patients in IMPACT and TRIBUTE, respectively, at 
baseline had experienced two or more exacerbations in the 
previous year. Having said that patients in TRIBUTE (FEV
1
 
36%) had more severe airflow limitation than in IMPACT 
(FEV
1
 46%). This difference in exacerbation history prob-
ably explains the greater relative and absolute reduction in 
exacerbations in IMPACT vs TRIBUTE when comparing 
triple to dual bronchodilator therapy. Furthermore, IMPACT 
compared identical LABA/LAMA moieties in both arms via 
the same once daily DPI device, whereas in TRIBUTE, the 
comparison was twice daily pMDI vs once daily DPI with 
different LABAs but the same LAMA, although in different 
dosing regimens. The other major difference between the 
studies was the pneumonia signal seen in IMPACT but not 
TRIBUTE in association with the FF moiety.
The relative increase in pneumonia risk seen in IMPACT 
and FULFIL but not TRIBUTE can be explained by the 
much higher degree of lipophilicity of FF than BDP (via its 
active metabolite 17-beclometasone monopropionate).17 The 
higher lipophilicity results in more prolonged ICS retention 
in the lung and in turn greater local immunosuppression in 
the presence of impaired mucociliary clearance and altered 
lung microbiome in patients with COPD (Figure 2). The 
differences in lipophilicity are reflected in inhaled phar-
macokinetics with terminal elimination half lives being 24 
hours vs 2.3 hours for FF and BMP, respectively.18,19 The 
prolonged duration of lung retention with FF is evident in 
patients with asthma where FeNO remains suppressed for 
up to 18 days after stopping treatment with FF compared to 
up to 7 days after stopping FP.20,21 It is unclear as to whether 
the more frequent exacerbating phenotype in IMPACT might 
in part explain the increased pneumonia risk, aside from the 
particular pharmacologic properties of FF. Interestingly the 
increased total and peripheral lung deposition associated 
with the extra fine formulation of BDP did not translate into 
an increased pneumonia risk in TRIBUTE. Another possi-
bility worth considering is that the extra fine BDP particles 
have lower oropharyngeal deposition than the more coarse 
particles of FF which could also alter the local microbiome. 
Studies are indicated to assess the benefit-risk profile of BDP/
FM/GLY when given via spacer device, particularly in more 
frequently exacerbating patients who may not only derive 
more benefit but also may be more prone to pneumonia.
Conclusions and the way forward
In summary, single inhaler triple therapy appears to be a suit-
able option for frequently exacerbating GOLD D patients, 
particularly those who have the eosinophilic phenotype. Since 
single triple inhaler has been shown to be consistently superior 
compared to ICS/LABA, we believe that there is probably 
no role moving forward for ICS/LABA in COPD guidelines. 
Hence, to simplify prescribing for COPD, we advocate a prag-
matic approach to reduce exacerbations using single inhaler 
therapy with either triple therapy or LABA/LAMA based on 
exacerbation history and blood eosinophils.1 For more symp-
tomatic GOLD B patients, we would advocate LABA/LAMA 
as a logical starting point given that this has been shown to 
be superior to LAMA or LABA alone.22,23 Nonetheless, we 
believe escalation to single triple inhaler might be warranted 
if patients continue to exacerbate on LABA/LAMA, although 
prospective trials are warranted to evaluate this strategy.
The beneficial effects of triple inhaler therapy compared 
to LABA/LABA are predominantly seen in ICS reducing 
eosinophil driven exacerbations rather than improving 
lung function, symptoms, or quality of life. ICS will not 
however impact on infective or pauci-inflammatory-related 
exacerbations. Raised blood eosinophil counts on their own 
should not be used to inform decision-making with regard 
to using ICS as triple therapy, but rather in conjunction 
with exacerbation history. In this regard, we would suggest 
Figure 2 Duration of lung retention with inhaled corticosteroids due to relative lipophilicity, which in turn determines pneumonia risk in COPD.
Note: Fluticasone furoate (FF), fluticasone propionate (FP), budesonide (BUD), and beclometasone dipropionate (BDP: via its active metabolite 17-BMP) – schematically 
depicted to reflect their respective kinetic terminal elimination half lives (FF.FP.BUD/BDP).
Abbreviation: 17-BMP, 17-beclometasone monopropionate.
)) )3 %8'%'3
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at least two exacerbations in the past year or one requiring 
hospital admission as a starting point. The difficult question 
is what eosinophil cutoff value should be used in a clinical 
setting to decide who goes onto triple therapy rather than 
LABA/LAMA. Based on the available data, we would 
advocate a pragmatic cutoff value for blood eosinophils of 
at least 300/µL, which in an average patient would trans-
late into a clinically meaningful reduction in exacerbation 
risk. However, trying to dichotomize what is a continuous 
variable may be somewhat arbitrary in terms of clinical 
decision-making in an individual patient. In such cases 
of eosinophilic COPD, it would be interesting to know if 
perhaps combining blood eosinophils with FeNO might 
improve the predictive value of ICS response, although in 
former smokers. At present, there are no defined thresholds 
for FeNO in COPD in terms of predicting ICS response in 
exacerbations, although this is likely to be lower than in 
asthma.24 In patients with so-called asthma COPD overlap a 
cutoff value of 22 ppb has been proposed.25 It is interesting 
to speculate if, eg, a combination of FeNO $20 ppb and 
blood eosinophils $150/µL might be more predictive of 
identifying an ICS responsive phenotype than perhaps using 
eosinophils alone. Further work is needed to more clearly 
identify such threshold values for FeNO in COPD.
Differences in terms of the device and dosing regimen 
should be taken into account when considering which for-
mulation to choose for an individual patient, along with the 
increased pneumonia risk associated with FF/VIL/UMEC. 
Any patient with COPD who has had a recent episode of 
pneumonia while taking ICS should have their treatment 
reappraised along with investigation to exclude concomitant 
bronchiectasis. Moreover, we believe that there are cogent 
reasons for not choosing to use FF as single triple therapy 
in patients who have COPD and bronchiectasis because of 
increased ICS lipophilicity and associated pneumonia risk in 
such individuals, especially when there are equally effective 
but safer options such as BDP and BUD.
Further studies are warranted to look at the potential 
benefit-risk profile of triple inhalers in GOLD B patients who 
experience an exacerbation despite already taking LABA/
LABA, particularly those with raised blood eosinophils. The 
KRONOS trial over 24 weeks was performed in predomi-
nantly GOLD B patients with FEV
1
 of 50% in whom 72% 
were taking prior ICS. There were significant improvements 
over 24 weeks in the primary end points comparing the co-
suspension formulations of BUD/FM/GLY versus BUD/FM 
amounting to a 104 mL difference in peak FEV
1
, and a 22 
mL difference comparing BUD/FM/GLY versus FM/GLY 
in trough FEV
1
.26 For the secondary end point BUD/FM/
GLY was associated with 52% significantly fewer moder-
ate to severe exacerbations compared to FM/GLY with no 
difference in pneumonia events (2% in both groups). The 
difference in exacerbations was more pronounced in patients 
with eosinophil counts above 150/µL. Comparing BUD/FM/
GLY versus BUD/FM there were 18% fewer exacerbations 
which was not significant. There was also a significant 1.22 
difference in SGRQ comparing BUD/FM/GLY vs FM/
GLY. Given the lack of any increased pneumonia risk with 
the triple, this in turn suggests that even in infrequently 
exacerbating patients there may be a role for BUD/FM/GLY 
being prescribed de novo rather than FM/GLY especially in 
eosinophilic patients. However these results should be inter-
preted with a degree of caution due to the 6 months duration 
and exacerbations being a secondary end point, along with 
44% of patients being reversible. The results ETHOS study 
(NCT02465567) are eagerly awaited which will look at two 
dose strengths of BUD/FM/GLY over 12 months compared 
to BUD/FM and FM/GLY in more severe patients, powered 
on exacerbations.
Finally, clinicians should always consider the possibility 
of de-escalating from triple therapy to LABA/LAMA in infre-
quently exacerbating noneosinophilic patients with COPD.
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